公司資料
Summit Therapeutics 股價、新聞與催化劑
- 股票代碼:
- SMMT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom with U
股票表現
16.69 USD (-1.30%)
收盤價
最後更新: 2026年10月1日
11.5B USD
市值
股價為何變動
截至 2026年10月1日，SMMT 下跌 1.30%，收於 $16.69。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Oncology-Focused Biopharmaceutical Company
Summit Therapeutics is building an oncology business around ivonescimab, a bispecific antibody designed to inhibit both PD-1 and VEGF. The company holds development and commercialization rights in the United States, Canada, Europe, Japan, and selected other territories through its partnership with Akeso.
Dual PD-1 and VEGF Mechanism
Ivonescimab combines immune-checkpoint blockade with anti-angiogenic activity in a single molecule. Its tetravalent design is intended to concentrate VEGF inhibition in the tumor microenvironment while preserving the antitumor immune activity associated with PD-1 blockade.
Broad Lung Cancer Program
The development program spans EGFR-mutated non-small cell lung cancer after tyrosine kinase inhibitor therapy and first-line squamous and nonsquamous disease. Multiple global Phase 3 studies are evaluating ivonescimab with chemotherapy or as part of other treatment combinations.
Expansion Across Solid Tumors
Summit is exploring ivonescimab beyond lung cancer through external combination studies and additional tumor types, including colorectal and head and neck cancers. Collaborations with other oncology companies provide access to complementary mechanisms without requiring Summit to internally own every combination asset.
Partner-Enabled Global Development
Akeso retains rights in China and other licensed territories and provides an extensive clinical dataset from its own studies. Summit uses those data, together with global trials conducted under its rights, to support regulatory submissions and commercial planning in major Western markets.
未來催化劑
- FDA PDUFA decision for ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer on November 14, 2026.
- Final progression-free-survival analysis and interim overall-survival analysis from the squamous HARMONi-3 cohort in the second half of 2026.
- Progression-free-survival and interim overall-survival analyses from the nonsquamous HARMONi-3 cohort in the first half of 2027.
- Initial data from the Arcus-sponsored ivonescimab combination study around mid-2027.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。